July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Goutham Sunny: VISION Trial and Beyond
Jul 5, 2025, 16:06

Goutham Sunny: VISION Trial and Beyond

Goutham Sunny, Assistant Professor at The Gujarat Cancer and Research Institute, shared a post on X:

“Tepotinib in METex14 Skipping NSCLC – VISION Trial and Beyond

Background:

  •  MET exon 14 skipping (METex14) occurs in ~3–4% of NSCLC cases
  •  Patients often have poor outcomes with standard therapies
  •  Tepotinib, an oral MET TKI, offers a targeted option

VISION Trial – Key Highlights:

  • Robust, durable efficacy in METex14+ NSCLC
  • Particularly effective in first-line setting
  • Consistent benefit across subgroups: Elderly and young, Asian patients, With/without brain metastases
  • Real-world evidence (RWE) supports trial data
  • Long-term safety manageable with preserved HRQOL (Health-Related Quality of Life)
  • Approved globally: Japan (2020), USA (2021 accelerated, 2024 full),

Mechanism:

  •  Selective MET inhibition blocks MET-driven signaling → halts tumor growth and spread

Clinical Use Insights:

  •  Tepotinib compares favorably vs chemo/IO in indirect analyses
  • Best outcomes observed when used early in treatment sequence
  •  Guidance provided for adverse event management (e.g., peripheral edema)

Pros:

  • Oral targeted therapy with durable response
  •  Effective even in brain metastases
  •  Real-world validation of efficacy
  • Safe long-term with preserved QoL
  •  First-line use may offer optimal outcomes

Cons:

  •  Not curative – requires ongoing therapy
  •  Resistance can develop
  • Side effects like edema require active management
  •  Limited head-to-head comparative trial data

Significance:

  • Tepotinib represents a major step forward for a previously underserved NSCLC subset
  • Supports biomarker-driven precision oncology
  • VISION + RWE help inform optimal treatment sequencing and real-world applicability”

Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer

Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara Jr., Emmanuel Adewusi, Xiuning Li

You can read the Full Article on Cancer Treatment Reviews

Goutham Sunny: VISION Trial and Beyond

More posts featuring Goutham Sunny